IBOV 185,229.17 ▼ 0.41% IPSA 11,381.18 ▲ 1.30% IPC MEX 63,375.93 ▼ 0.78% MERVAL 3,021,926 ▼ 1.29% COLCAP 2,548.22 ▲ 1.05% BVL PERÚ 60,023.65 ▼ 1.13% USD/BRL5.14▲ 0.02% USD/MXN17.22▼ 0.01% USD/CLP959.00▼ 0.31% USD/COP3,181▲ 0.20% USD/PEN3.37▼ 0.01% USD/ARS1,514— 0.00% USD/UYU40.16▲ 2.99% USD/PYG5,906▲ 3.00% USD/BOB9.95▲ 1.26% USD/DOP58.83▲ 2.40% USD/CRC444.45▲ 2.50% USD/GTQ7.63▲ 3.11% USD/HNL26.85▲ 3.16% USD/NIO36.62— 0.00% USD/VES847.44▼ 0.13% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD 157.28 — 0.00% USD/TTD6.75▲ 2.45% EUR/BRL5.91▲ 0.04% BRENT 88.88 ▼ 0.03% WTI 83.11 ▼ 0.11% IRON ORE 161.91 — — COPPER 6.61 ▲ 0.03% GOLD 4,461 ▲ 1.78% SILVER 65.59 ▲ 1.26% SOY 1,184 ▲ 3.20% CORN 480.50 ▲ 10.02% WHEAT 655.00 ▲ 3.93% COFFEE 317.25 ▼ 5.51% SUGAR 16.43 ▼ 1.79% ORANGE JUICE 138.55 ▼ 0.47% COTTON 85.03 ▲ 2.33% COCOA 5,719 ▲ 3.18% BEEF 223.60 ▼ 3.93% CATTLE 339.10 ▼ 3.16% LITHIUM 75.20 ▲ 1.47% PETR4 41.64 ▼ 0.05% VALE3 72.97 ▲ 0.83% ITUB4 38.60 ▼ 1.03% BBDC4 16.85 ▲ 0.36% ABEV3 14.89 ▼ 0.80% BBAS3 19.37 ▲ 0.47% B3SA3 14.26 ▼ 0.21% WEGE3 47.59 ▲ 0.49% PRIO3 59.14 ▼ 0.19% SUZB3 41.33 ▲ 2.35% RENT3 34.68 ▼ 0.09% AZZA3 15.89 ▼ 2.63% CSAN3 3.22 ▼ 1.83% RAIZ4 0.25 — 0.00% PCAR3 2.75 ▼ 0.36% GMAT3 3.65 ▼ 1.08% PSSA3 48.13 ▼ 0.54% CVCB3 1.33 ▼ 2.92% POSI3 3.36 ▲ 2.44% SLCE3 13.34 ▲ 0.30% NATU3 8.14 ▼ 0.73% IBOV 185,229.17 ▼ 0.41% IPSA 11,381.18 ▲ 1.30% IPC MEX 63,375.93 ▼ 0.78% MERVAL 3,021,926 ▼ 1.29% COLCAP 2,548.22 ▲ 1.05% BVL PERÚ 60,023.65 ▼ 1.13% USD/BRL 5.16 ▲ 0.01% USD/MXN 17.06 ▼ 0.24% USD/CLP 913.98 ▲ 0.04% USD/COP 3,140 ▲ 0.03% USD/PEN 3.36 ▼ 0.66% USD/ARS 1,493 ▲ 0.10% USD/UYU 40.27 ▲ 1.24% USD/PYG 5,939 ▲ 1.68% USD/BOB 11.64 ▼ 0.76% USD/DOP 58.34 ▲ 1.25% USD/CRC 445.92 ▲ 0.89% USD/GTQ 7.62 ▲ 2.21% USD/HNL 26.79 ▲ 1.57% USD/NIO 36.62 ▲ 0.69% USD/VES 762.44 ▼ 0.13% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.28 — 0.00% USD/TTD 6.70 ▲ 0.61% EUR/BRL 5.95 ▲ 1.01% BRENT 88.88 ▼ 0.03% WTI 83.11 ▼ 0.11% IRON ORE 161.91 — — COPPER 6.61 ▲ 0.03% GOLD 4,461 ▲ 1.78% SILVER 65.59 ▲ 1.26% SOY 1,184 ▲ 3.20% CORN 480.50 ▲ 10.02% WHEAT 655.00 ▲ 3.93% COFFEE 317.25 ▼ 5.51% SUGAR 16.43 ▼ 1.79% ORANGE JUICE 138.55 ▼ 0.47% COTTON 85.03 ▲ 2.33% COCOA 5,719 ▲ 3.18% BEEF 223.60 ▼ 3.93% CATTLE 339.10 ▼ 3.16% LITHIUM 75.20 ▲ 1.47% PETR4 41.64 ▼ 0.05% VALE3 72.97 ▲ 0.83% ITUB4 38.60 ▼ 1.03% BBDC4 16.85 ▲ 0.36% ABEV3 14.89 ▼ 0.80% BBAS3 19.37 ▲ 0.47% B3SA3 14.26 ▼ 0.21% WEGE3 47.59 ▲ 0.49% PRIO3 59.14 ▼ 0.19% SUZB3 41.33 ▲ 2.35% RENT3 34.68 ▼ 0.09% AZZA3 15.89 ▼ 2.63% CSAN3 3.22 ▼ 1.83% RAIZ4 0.25 — 0.00% PCAR3 2.75 ▼ 0.36% GMAT3 3.65 ▼ 1.08% PSSA3 48.13 ▼ 0.54% CVCB3 1.33 ▼ 2.92% POSI3 3.36 ▲ 2.44% SLCE3 13.34 ▲ 0.30% NATU3 8.14 ▼ 0.73%
since 2009
Sunday, September 20, 2026

Fleury Expands Medical Diagnostics Empire with R$130 million Acquisition

By · November 28, 2024 · 2 min read

The LatAm Brief

One email, every weekday morning. What moved in Latin American markets, politics and expat life.

Yesterday’s subject line: “Bolivia's 83% fuel shock, hours after the IMF loan”

Free. We send a confirmation link first — nothing arrives until you click it. Unsubscribe with one click in any edition. If you stop opening us for 30 days we stop sending by ourselves, as we assume the interest is no longer there. See our privacy policy. We never share your email.

Fleury Group strengthens its market position through a calculated R$130 million ($22.4 million) acquisition of Confiance Medical Diagnostics. The deal adds 25 diagnostic centers in São Paulo’s prosperous interior region to Fleury’s portfolio.

The acquisition targets a lucrative healthcare market where 47% of the 3.1 million residents hold private health insurance. This rate surpasses both the national average of 25% and São Paulo state’s 42%, highlighting the region’s economic strength.

Fleury secured the deal at 5.5 times EBITDA, factoring in cost synergies through centralized test processing at their São Paulo technical center.

The company maintains its debt-to-EBITDA ratio at 1.2x, demonstrating sound financial management. The purchased network processes 5.8 million tests annually across seven cities, including Campinas and surrounding municipalities.

Confiance’s annual revenue reaches R$103 million ($17.8 million), serving middle to high-income patients through both physical locations and home services.

Fleury Expands Medical Diagnostics Empire with R$130 million Acquisition
Fleury Expands Medical Diagnostics Empire with R$130 million Acquisition.
RT
Ask Rio Times
Latin American markets, currencies and companies.
Open the full Ask Rio Times →

Home testing services show particular promise, already generating 7.8% of Fleury‘s gross revenue across their operations. This segment equals the output of 60 physical locations, reflecting changing consumer preferences in healthcare delivery.

Fleury’s Strategic Growth

Fleury’s expansion strategy focuses on maintaining dividend payments while avoiding excessive debt exposure. The company allocates 6% of revenue to capital expenditures, primarily targeting technology upgrades and infrastructure maintenance.

This marks Fleury’s nineteenth acquisition since 2017, with total investments reaching R$2 billion ($344.8 million). The company’s broader healthcare portfolio includes specialized medical clinics offering orthopedics, ophthalmology, and oncology services.

The Campinas region represents a strategic growth opportunity as one of Brazil‘s most dynamic economic hubs. Fleury plans to retain the Confiance brand while exploring organic growth opportunities in other interior cities.

Fleury’s financial performance remains solid, with R$5.8 billion ($1 billion) revenue and R$532 million ($91.7 million) net profit in the first nine months. Their specialized medical services division contributed R$600 million ($103.4 million) during this period.

The deal strengthens Fleury’s competitive position in a region known for its robust healthcare demand and economic vitality. This strategic move aligns with their goal of expanding quality diagnostic services while maintaining operational efficiency.

Live Company IntelligenceFleury S.A. — the full investor dossierInside: live share price, market cap, three-year financials, valuation, ESG and peer benchmarks — plus the latest Rio Times coverage.
F
◆ Live Company Intelligence
Fleury
SA: FLRY3FLRY3HealthcareDiagnostics & Research28,000 employees
R$11.62B
Market cap

Valuation & profitability

Market capR$11.62B
Revenue (TTM)R$8.79B
P / E ratio18.4
Profit margin8.0%
Return on equity12.6%

Price & risk

52-wk low
$13.01
52-wk high
$21.63
Beta (volatility)0.21
200-day average$16.50

Revenue trend · 6y

20202025
Latest R$8.29B

Ownership

Institutions28.3%
Shares outstanding544M

Dividend

Yield5.6%
Payout ratio90.7%
Fwd. annual$1.61
What Fleury does. Fleury S.A., together with its subsidiaries, engages in the provision of diagnostic imaging, clinical analysis, fertility, and infusions services in Brazil. It operates in two segments, Diagnostic Medicine and Integrated Medicine. The company also provides medical services in the areas of diagnostics, laboratory support, infusions, clinical analyses, health management, healthcare, assistance medicine,…
Data: RT fundamentals (FLRY3.SA) · figures in BRL · as of 20 Sep 2026More company intelligence →

This article was produced by The Rio Times’ automated newsroom system. How we use AI · Report an error

LatAm Markets: Live Signals → — real-time movers, turnover leaders and FX across Latin America.

Read More from The Rio Times

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.